These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

680 related articles for article (PubMed ID: 16372228)

  • 1. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relevance of TSH receptor stimulating and blocking autoantibody measurement for the prediction of relapse in Graves' disease.
    Schott M; Minich WB; Willenberg HS; Papewalis C; Seissler J; Feldkamp J; Bergmann A; Scherbaum WA; Morgenthaler NG
    Horm Metab Res; 2005 Dec; 37(12):741-4. PubMed ID: 16372227
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of remission or relapse for Graves' hyperthyroidism by the combined determination of stimulating, blocking and binding TSH-receptor antibodies after the withdrawal of antithyroid drug treatment.
    Wallaschofski H; Miehle K; Mayer A; Tuschy U; Hentschel B; Paschke R
    Horm Metab Res; 2002 Jul; 34(7):383-8. PubMed ID: 12189586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Levels of autoantibodies against human TSH receptor predict relapse of hyperthyroidism in Graves' disease.
    Schott M; Morgenthaler NG; Fritzen R; Feldkamp J; Willenberg HS; Scherbaum WA; Seissler J
    Horm Metab Res; 2004 Feb; 36(2):92-6. PubMed ID: 15002058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Stimulating and blocking thyroid-stimulating hormone (TSH) receptor autoantibodies from patients with Graves' disease and autoimmune hypothyroidism have very similar concentration, TSH receptor affinity, and binding sites.
    Morgenthaler NG; Ho SC; Minich WB
    J Clin Endocrinol Metab; 2007 Mar; 92(3):1058-65. PubMed ID: 17179194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Similar clinical performance of a novel chimeric thyroid-stimulating hormone receptor bioassay and an automated thyroid-stimulating hormone receptor binding assay in Graves' disease.
    Kamijo K; Murayama H; Uzu T; Togashi K; Olivo PD; Kahaly GJ
    Thyroid; 2011 Dec; 21(12):1295-9. PubMed ID: 22066477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of smoking on the course of Graves' disease after withdrawal of antithyroid drugs.
    Quadbeck B; Roggenbuck U; Janssen OE; Hahn S; Mann K; Hoermann R;
    Exp Clin Endocrinol Diabetes; 2006 Sep; 114(8):406-11. PubMed ID: 17039420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sensitive thyrotropin and thyrotropin-receptor antibody determinations one month after discontinuation of antithyroid drug treatment as predictors of relapse in Graves' disease.
    Quadbeck B; Hoermann R; Roggenbuck U; Hahn S; Mann K; Janssen OE;
    Thyroid; 2005 Sep; 15(9):1047-54. PubMed ID: 16187913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay.
    Maugendre D; Massart C
    Clin Endocrinol (Oxf); 2001 Jan; 54(1):89-96. PubMed ID: 11167931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical results of anti-inflammatory therapy in Graves' ophthalmopathy and association with thyroidal autoantibodies.
    Eckstein AK; Plicht M; Lax H; Hirche H; Quadbeck B; Mann K; Steuhl KP; Esser J; Morgenthaler NG
    Clin Endocrinol (Oxf); 2004 Nov; 61(5):612-8. PubMed ID: 15521965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in patients with de novo Graves' disease.
    Hovens GC; Buiting AM; Karperien M; Ballieux BE; van der Pluijm G; Pereira AM; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):429-35. PubMed ID: 16584516
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease.
    Bossowski A; Stasiak-Barmuta A; Urban M
    Horm Res; 2005; 64(4):189-97. PubMed ID: 16220002
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical value of M22-based assays for TSH-receptor antibody (TRAb) in the follow-up of antithyroid drug treated Graves' disease: comparison with the second generation human TRAb assay.
    Massart C; Gibassier J; d'Herbomez M
    Clin Chim Acta; 2009 Sep; 407(1-2):62-6. PubMed ID: 19576193
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
    Rink T; Holle LH; Schroth HJ; Garth H
    Nuklearmedizin; 1998 May; 37(3):90-4. PubMed ID: 9604228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved prediction of relapse of Graves' thyrotoxicosis by combined determination of TSH receptor and thyroperoxidase antibodies.
    Schott M; Eckstein A; Willenberg HS; Nguyen TB; Morgenthaler NG; Scherbaum WA
    Horm Metab Res; 2007 Jan; 39(1):56-61. PubMed ID: 17226115
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thyroid-stimulating antibody and TSH-binding inhibitor immunoglobulin in 277 Graves' patients and in 686 normal subjects.
    Takasu N; Oshiro C; Akamine H; Komiya I; Nagata A; Sato Y; Yoshimura H; Ito K
    J Endocrinol Invest; 1997 Sep; 20(8):452-61. PubMed ID: 9364248
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antibodies against TSH receptors (TRAb) as indicators in prognosing the effectiveness of Tiamazol therapy for Grave's Disease].
    Bojarska-Szmygin A; Ciechanek R
    Wiad Lek; 2003; 56(7-8):303-7. PubMed ID: 14969154
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Application of a bioassay with CHO cells for the routine detection of stimulating and blocking autoantibodies to the TSH-receptor.
    Morgenthaler NG; Pampel I; Aust G; Seissler J; Scherbaum WA
    Horm Metab Res; 1998 Mar; 30(3):162-8. PubMed ID: 9566861
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of M22-based ELISA and human-TSH-receptor-based luminescence assay for the measurement of thyrotropin receptor antibodies in patients with thyroid diseases.
    Liu C; Hermsen D; Domberg J; Graeber C; Hautzel H; Duan Y; Xu KF; Liu CP; Mao XD; Cupisti K; Scherbaum WA; Schott M
    Horm Metab Res; 2008 Jul; 40(7):479-83. PubMed ID: 18504673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Antithyrotropin receptor antibodies in a series of Basedow's disease].
    Vidal E; Antoine E; Nadalon S; Cevallos R; Bournaud E; Vandroux JC; Bordessoule D; Loustaud V; Weinbreck P; Liozon F
    Ann Med Interne (Paris); 1988; 139(5):331-5. PubMed ID: 2462393
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 34.